MARIOTTINI, ALICE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.834
EU - Europa 2.442
AS - Asia 2.436
SA - Sud America 312
AF - Africa 80
OC - Oceania 31
Continente sconosciuto - Info sul continente non disponibili 1
Totale 8.136
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.789
RU - Federazione Russa 1.149
CN - Cina 759
SG - Singapore 657
IT - Italia 499
HK - Hong Kong 355
KR - Corea 287
BR - Brasile 257
IE - Irlanda 186
VN - Vietnam 109
SE - Svezia 107
DE - Germania 95
PL - Polonia 91
IN - India 89
FI - Finlandia 75
NL - Olanda 66
FR - Francia 50
ID - Indonesia 44
JO - Giordania 40
GB - Regno Unito 35
AU - Australia 30
MA - Marocco 27
CA - Canada 24
AR - Argentina 22
ES - Italia 21
CH - Svizzera 18
IR - Iran 17
MX - Messico 17
TR - Turchia 17
ZA - Sudafrica 14
CI - Costa d'Avorio 13
EC - Ecuador 13
EG - Egitto 12
UA - Ucraina 11
BD - Bangladesh 10
JP - Giappone 10
AT - Austria 9
BJ - Benin 7
IQ - Iraq 6
SA - Arabia Saudita 5
CO - Colombia 4
KE - Kenya 4
PH - Filippine 4
PK - Pakistan 4
PY - Paraguay 4
UY - Uruguay 4
UZ - Uzbekistan 4
CL - Cile 3
GR - Grecia 3
LT - Lituania 3
MK - Macedonia 3
MY - Malesia 3
SK - Slovacchia (Repubblica Slovacca) 3
VE - Venezuela 3
BY - Bielorussia 2
CZ - Repubblica Ceca 2
HN - Honduras 2
HU - Ungheria 2
IL - Israele 2
KG - Kirghizistan 2
LB - Libano 2
LI - Liechtenstein 2
NO - Norvegia 2
PE - Perù 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BE - Belgio 1
BG - Bulgaria 1
BH - Bahrain 1
CY - Cipro 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
ET - Etiopia 1
GE - Georgia 1
IM - Isola di Man 1
IS - Islanda 1
KW - Kuwait 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
NG - Nigeria 1
NP - Nepal 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
RO - Romania 1
SI - Slovenia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 8.136
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.082
Singapore 487
Ashburn 317
Hong Kong 316
Hefei 309
Seoul 287
Dublin 186
Beijing 129
Chandler 112
Fairfield 99
Milan 92
Florence 84
Warsaw 83
Kent 82
Los Angeles 64
Buffalo 52
Munich 51
Moscow 50
Altamura 45
Lawrence 45
Mumbai 39
Boston 37
Ho Chi Minh City 36
Seattle 35
Rome 34
Wilmington 33
Cambridge 32
Dallas 32
Jakarta 32
Woodbridge 32
Princeton 31
Lappeenranta 29
Paris 29
São Paulo 28
Turku 28
Melbourne 27
Hanoi 26
Houston 25
Casablanca 24
New York 22
Shanghai 22
The Dalles 19
Bengaluru 18
Clifton 18
Helsinki 18
Frankfurt am Main 17
Chicago 16
Abidjan 13
West Jordan 13
Rio de Janeiro 12
Bern 11
Hamburg 11
Barcelona 10
Chennai 10
Dearborn 10
Johannesburg 10
Istanbul 9
Medford 9
Modena 9
Belo Horizonte 8
Cairo 8
London 8
Naples 8
Pune 8
San Diego 8
Tokyo 8
Amsterdam 7
Ann Arbor 7
Brooklyn 7
Catania 7
Cotonou 7
Denver 7
Norwalk 7
Ottawa 7
Porto Alegre 7
Quito 7
Stockholm 7
Tehran 7
Toronto 7
Trieste 7
Atlanta 6
Bologna 6
Burgum 6
Genoa 6
Manchester 6
Nuoro 6
Romola 6
Gdansk 5
Guangzhou 5
Livorno 5
Tianjin 5
Turin 5
Amman 4
Ankara 4
Campinas 4
Da Nang 4
Dong Ket 4
Falls Church 4
Goiânia 4
Guayaquil 4
Totale 5.091
Salva come PNG Salva come JPEG
Nome #
K index improves MS diagnosis and supports the differential diagnosis between MS and MS-like syndromes. 315
The TCR Repertoire Reconstitution in Multiple Sclerosis: Comparing One-Shot and Continuous Immunosuppressive Therapies 189
Safety and efficacy of autologous hematopoietic stem cell transplantation following natalizumab discontinuation in aggressive Multiple Sclerosis 183
Effect of the COVID-19 pandemic on disease activity in multiple sclerosis patients treated with hematopoietic stem cell transplantation 175
Disease reactivation following fingolimod withdrawal in multiple sclerosis: Two case reports. 175
Clinical and paraclinical findings in a case series of MOGAD: Exploring the presence of perivenular brain white matter lesions 166
Clinical characteristics predicting relapses following disease modifying therapies discontinuation in multiple sclerosis: a monocentric cohort study 165
Neuropsychological assessment in aggressive multiple sclerosis treated with stem cell transplantation 159
Safety and tolerability of SARS-Cov-2 vaccination in patients with myasthenia gravis: A multicenter experience 155
Anti-SARS-Cov2 vaccination at the time of the COVID-19 pandemic: suspected adverse events reporting is the milestone of post-marketing surveillance 155
Spinal cord size as promising biomarker of disability outcomes after hematopoietic stem cell transplantation in multiple sclerosis 154
Leptomeningeal enhancement in multiple sclerosis: a focus on patients treated with hematopoietic stem cell transplantation 153
Effect of disease-modifying treatments on antibody-mediated response to anti- COVID19 vaccination in people with multiple sclerosis 153
Safety and effectiveness of the booster dose of mRNA COVID-19 vaccines in people with multiple sclerosis: A monocentric experience 152
Severe disease reactivation in two multiple sclerosis patients after natalizumab withdrawal was not halted by monthly administrations of cyclophosphamide - two case reports 145
Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis 140
Early Morbidity of Autologous Haematopoietic Stem Cell Transplantation in Multiple Sclerosis- A Real World Experience 140
Intermediate-Intensity Autologous Hematopoietic Stem Cell Transplantation Reduces Serum Neurofilament Light Chains and Brain Atrophy in Aggressive Multiple Sclerosis. 138
Investigating Serum sHLA-G Cooperation With MRI Activity and Disease-Modifying Treatment Outcome in Relapsing-Remitting Multiple Sclerosis 137
Efficacy of autologous hematopoietic stem cell transplantation in secondary progressive Multiple sclerosis 137
Successful switch to ofatumumab after liver injury associated with ocrelizumab treatment in multiple sclerosis: a case report 135
Autologous Hematopoietic Stem Cell Transplantation in Active Multiple Sclerosis: A Real-world Case Series 133
Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis 130
Case report: 3D intracranial vessel wall MRI in Susac syndrome: potential relevance for diagnosis and therapeutic management 130
Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing–remitting multiple sclerosis 129
Acute unilateral sixth cranial nerve palsy and headache as initial manifestations of carcinomatous meningitis. 128
Reconstitution of natural or vaccination-driven immunity after aHSCT in multiple sclerosis 128
Autologous hematopoietic stem cell transplantation versus low-dose immunosuppression in secondary-progressive multiple sclerosis 124
COVID-19 in patients with aggressive MS treated with aHSCT: a multi-center study 123
Comparative long term efficacy of beta interferons and azathioprine in relapsing-remitting Multiple sclerosis: single center retrospective 25 year evaluation 123
Real Life comparative evaluation of dimethyl fumarate efficacy and tolerability in relapsing remitting multiple sclerosis patients switching from other treatments 122
CNS inflammation during relapsing remitting multiple sclerosis (RRMS): a molecular and cellular analysis of ex vivo CSF T lymphocyte expansions 121
Evaluation of dimethyl fumarate efficacy and safety in patients with relapsing remitting multiple sclerosis switching from other treatments 119
Incidence of malignant neoplasms and mortality in people affected by multiple sclerosis in the epoch of disease-modifying treatments: a population-based study on Tuscan residents 118
Prevalence of disability improvement as a potential outcome for multiple sclerosis trials 115
Sustained disease remission after discontinuation of disease modifying treatments in relapsing-remitting multiple sclerosis. 114
Disease Modifying Strategies in Multiple Sclerosis: New Rays of Hope to Combat Disability? 113
Management of viral reactivation in multiple sclerosis patients after autologous transplantation with BEAM/ATG conditioning regimen 112
Soluble factor profile in Natalizumab treated MS patients: increased Th1 promoting factors and sHLAg 109
Sustained disease remission in multiple sclerosis after autologous haematopoietic stem cell transplantation. The Italian experience 106
intermediate intensity regimen in autologous HSCT for severe Multiple Sclerosis: a a large, single center experience 104
Long-Term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis 104
Antibody-mediated cell depletion therapies in multiple sclerosis 104
Hematopoietic Stem Cell Transplantation for the Treatment of Autoimmune Neurological Diseases: An Update 102
Haematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis: Recent Advances 101
Immunosenescence and Autoimmunity: Exploiting the T-Cell Receptor Repertoire to Investigate the Impact of Aging on Multiple Sclerosis 100
Impact of autologous haematopoietic stem cell transplantation on fertility in aggressive multiple sclerosis 98
Safety profile of autologous haematopoietic stem cell transplantation following natalizumab therapy in aggressive forms of multiple sclerosis 97
Relevance of Pathogenetic Mechanisms to Clinical Effectiveness of B-Cell-Depleting Monoclonal Antibodies in Multiple Sclerosis 95
Impact of new DMAs on the safety profile of patients undergoing autologous haematopoietic stem cell transplantation for Multiple Sclerosis 95
Purely myeloablative conditioning regimen in aggressive multiple sclerosis: two case reports 95
Challenges in Diagnosis of COVID-19 Pneumonia under Ocrelizumab and De-Risking Strategies in Multiple Sclerosis—The Elephant Is (Still) in the Room 95
Exploring the therapeutic potential of autologous hematopoietic stem cell transplantation in progressive multiple sclerosis—a systematic review 94
Immune cell reconstitution following autologous hematopoietic stem cell transplantation in multiple sclerosis 94
Intermediate intensity regimen in autologous HSCT for severe multiple sclerosis: a large, single center experience 93
Magnetic Resonance intracranial Vessel Wall Imaging (VWI) in Susac Syndrome: potential relevance for diagnosis and therapeutic management. 91
Autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK: A 20‐year retrospective analysis of activity and haematological outcomes from the British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT) 88
The role of chemotherapy in hematopoietic stem cell transplantation for autoimmune disorders: From lymphoablative to myeloablative conditioning protocols 85
Should autologous hematopoietic stem cell transplantation be offered as a first-line disease modifying therapy to patients with multiple sclerosis? 83
Thymic hyperplasia after autologous hematopoietic stem cell transplantation in multiple sclerosis: a case series 80
Low positive predictive value of Multiple Sclerosis diagnostic criteria in demyelinating syndromes with red flags of better explanation. 78
Non-inferiority analysis of subcutaneous versus intravenous 300 mg monthly natalizumab administration: A post hoc analysis of the REFINE study 77
Haematopoietic Stem Cell Transplantation for Multiple Sclerosis: Current Status 76
Preface 74
Comparative efficacy of subcutaneous versus intravenous natalizumab on annualized relapse rate: a post-hoc analysis of the REFINE study 69
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder — recommendations from ECTRIMS and the EBMT 68
Aggressive MS and Autologous HSCT: A review on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation 66
Effectiveness of Autologous Hematopoietic Stem Cell Transplantation versus Alemtuzumab and Ocrelizumab in Relapsing Multiple Sclerosis: A Single Center Cohort Study 51
CD20+ T Cells in Multiple Sclerosis: From Pathogenesis to Treatment-Induced Depletion 45
Autologous haematopoietic stem cell transplantation affects long-term progression independent of relapse activity in aggressive multiple sclerosis: a comparative matched study 29
Real-world effectiveness of autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK 11
BEAM/ATG or cyclophosphamide/ATG as conditioning regimen in autologous haemopoietic stem cell transplantation for multiple sclerosis: a retrospective analysis of the EBMT autoimmune diseases working party 10
Totale 8.270
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.829
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.829
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202179 0 0 0 0 0 8 13 14 14 16 6 8
2021/2022205 2 15 8 9 2 8 5 33 18 7 32 66
2022/2023683 44 112 45 34 35 126 104 36 102 1 27 17
2023/2024631 16 75 69 35 53 47 24 106 29 66 77 34
2024/20253.545 126 327 201 503 828 561 109 230 145 96 167 252
2025/20262.808 547 666 609 523 429 34 0 0 0 0 0 0
Totale 8.270